Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | KMO | O15229 | 1/20 | 0.57 |
| ▸ | ADK | P55263 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK3 | P52333 | 1/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.47 |
| ▸ | MTOR | P42345 | 2/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | BCR | P11274 | 1/20 | 0.46 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30828973 | 0.93 | CYP2C19 (0.53) | CYP2C19KMOADKHTTSMN1; SMN2 | |
| SCHEMBL26647473 | 0.93 | CYP2C19 (0.53) | CYP2C19KMOADKHTTSMN1; SMN2 | |
| SCHEMBL6800730 | 0.87 | KDR (0.53) | CYP2C19KMOADKHTTSMN1; SMN2 | |
| SCHEMBL31110333 | 0.86 | CYP2C19 (0.68) | CYP2C19KMOHTTSMN1; SMN2KDM4E | |
| SCHEMBL6803221 | 0.83 | KDR (0.55) | CYP2C19KMOADKHTTSMN1; SMN2 | |
| SCHEMBL19004851 | 0.82 | AKT1 (0.47) | CYP2C19ADKSMN1; SMN2JAK2JAK3 | |
| SCHEMBL807296 | 0.82 | SMN1; SMN2 (0.50) | SMN1; SMN2JAK2JAK3CRHBPCRHR2 | |
| SCHEMBL30579439 | 0.82 | SMN1; SMN2 (0.50) | SMN1; SMN2JAK2JAK3CRHBPCRHR2 | |
| SCHEMBL4137311 | 0.81 | KMO (0.61) | CYP2C19KMOADKHTTSMN1; SMN2 | |
| SCHEMBL5889085 | 0.81 | SMN1; SMN2 (0.53) | SMN1; SMN2JAK2JAK3CYP1A2CRHBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110831600-B | Indole AHR inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2023-10-17 | — | — | CN | disclosed |
| US-11612604-B2 | Methods of treating cancer with PLK4 inhibitors | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) | 2023-03-28 | — | — | US | disclosed |
| EP-3283482-B1 | PLK4 INHIBITORS | LUDWIG INST FOR CANCER RES LTD (CH) | 2022-04-06 | — | — | EP | disclosed |
| WO-2022011274-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5 | GOLDFINCH BIO, INC. (US) | 2022-01-13 | — | — | WO | disclosed |
| US-20200299282-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | ANTIDOTE IP HOLDINGS LLC (US) | 2020-09-24 | — | — | US | disclosed |
| EP-3362450-B1 | N1- AND N7-SUBSTITUTED SIBIRILINE DERIVATIVES AND THEIR USE AS INHIBITORS OF CELLULAR NECROPTOSIS | INST NAT SANTE RECH MED (FR) | 2020-07-01 | — | — | EP | disclosed |
| US-10457678-B2 | Substituted pyrrolo[2,3-b]pyridines as inhibitors of cellular necroptosis | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2019-10-29 | — | — | US | disclosed |
| US-20180312502-A1 | N1-And N7-Substituted Sibiriline Derivatives And Their Use As Inhibitor Of Cellular Necroptosis | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2018-11-01 | — | — | US | disclosed |
| EP-3362450-A1 | N1- AND N7-SUBSTITUTED SIBIRILINE DERIVATIVES AND THEIR USE AS INHIBITOR OF CELLULAR NECROPTOSIS | Institut National de la Sante et de la Recherche Medicale (INSERM) (FR) | 2018-08-22 | — | — | EP | disclosed |
| EP-3283482-A1 | PLK4 INHIBITORS | Ludwig Institute for Cancer Research Ltd (CH) | 2018-02-21 | — | — | EP | disclosed |
| WO-2008078100-A2 | TRICYCLIC AMINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-07-03 | — | — | WO | disclosed |
| US-7115597-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20040063720-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2004-04-01 | — | — | US | disclosed |
| US-20020137755-A1 | Tyrosine kinase inhibitors | BILODEAU MARK T (US) | 2002-09-26 | — | — | US | disclosed |
| CN-1010947-B | PROCESS FOR PREPN. OF PYRIDOPYRIMIDINES COMPOUNDS | BAYER AG (DE) | 1990-12-26 | — | — | CN | disclosed |
| EP-0232025-A2 | Dihydropyridine anti-ischaemic and antihypertensive agents | Pfizer Limited (GB) | 1987-08-12 | — | — | EP | disclosed |
| CN-86100279-A | The method for preparing the Pyridopyrimidine compounds | — | 1986-11-19 | — | — | CN | disclosed |
| US-4621082-A | Pyridopyrimidines, pharmaceutical compositions and use | BAYER AKTIENGESELLSCHAFT (DE) | 1986-11-04 | — | — | US | disclosed |
| US-4565864-A | INTERMEDIATES FOR BRONCHODILATORS | RIKER LABORATORIES, INC. (US) | 1986-01-21 | — | — | US | disclosed |
| US-4503050-A | BRONCHODILATORS | RIKER LABORATORIES, INC. (US) | 1985-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11612604-B2 | Methods of treating cancer with PLK4 inhibitors | PLK4, PLK2, PLK3 | CYP2C19 4666/4885KMO 4107/4885ADK 326/4885 |
| US-10457678-B2 | Substituted pyrrolo[2,3-b]pyridines as inhibitors of cellular necroptosis | CASP7, PARK7, RIPK3 | CYP2C19 4521/4885KMO 1297/4885ADK 2182/4885 |
| US-20020137755-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | CYP2C19 4843/4885KMO 1685/4885ADK 666/4885 |
| US-20180312502-A1 | N1-And N7-Substituted Sibiriline Derivatives And Their Use As Inhibitor Of Cellular Necroptosis | CASP7, RIPK3, PARK7 | CYP2C19 4572/4885KMO 3560/4885ADK 2061/4885 |
| US-20040063720-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | CYP2C19 4843/4885KMO 1685/4885ADK 666/4885 |
| US-20200299282-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | VHL, TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CYP2C19 2462/4885KMO 3163/4885ADK 2804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.